98%
921
2 minutes
20
Effective drugs for the clinical treatment of hepatic fibrosis have not yet been identified. Salvianic acid A (SAA) protective mechanisms primarily include anti-inflammation, anti-oxidative stress, and modulation of immune system function. Metabolic dysfunction is well recognized as the driver for hepatic fibrosis. However, the precise action mode and underlying mechanism of SAA in modulating hepatic metabolism to combat hepatic fibrosis remain incompletely understood. This study aimed to investigate the metabolic mechanism by which SAA improves hepatic fibrosis based on metabolomics and transcriptomics profiling. A mouse model of carbon tetrachloride (CCl)-induced hepatic fibrosis mouse model was established, and protective effects of SAA were evaluated through pathological characteristics. Integrated metabolomics and transcriptomics analysis revealed three key altered metabolic pathways: bile secretion, carbohydrate digestion and absorption, and regulation of lipolysis in adipocytes. SAA modulated the bile secretion pathway, dependent on reducing water channel protein Aqp1, cholesterol synthesis enzyme Hmgcr and Na/K-ATPase enzyme Atp1a3, accompanied by up-regulating metabolites glutathione and glucose levels. SAA also regulated carbohydrate digestion and absorption by decreasing the glucose homeostasis-related Akt3, essential enzyme G6pc for gluconeogenesis/glycogenolysis and glucose transporter Atp1a3 with a concomitant increase of metabolites D-galactose, maltose, and sucrose levels. Moreover, SAA improved lipolysis in adipocytes in liver fibrosis through inhibiting lipolysis related Prkg1, lipid transporter Fabp4, lipolysis-associated Akt3 and increasing lipolysis mediator Adrb3, along with upregulated levels of metabolites adenosine monophosphate and norepinephrine. In conclusion, SAA alleviates hepatic fibrosis through modulating metabolic disorders, mainly relying on the metabolic improvements of bile secretion, carbohydrate digestion and absorption and adipocyte lipolysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.taap.2025.117398 | DOI Listing |
Eur J Gastroenterol Hepatol
August 2025
Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.
Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.
View Article and Find Full Text PDFN Engl J Med
September 2025
Akero Therapeutics, South San Francisco, CA.
N Engl J Med
September 2025
Affiliated Hospital of Jiaxing University, Jiaxing, China.
JMIR Med Inform
September 2025
College of Medical Informatics, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China, 86 13500303273.
Background: Cirrhosis is a leading cause of noncancer deaths in gastrointestinal diseases, resulting in high hospitalization and readmission rates. Early identification of high-risk patients is vital for proactive interventions and improving health care outcomes. However, the quality and integrity of real-world electronic health records (EHRs) limit their utility in developing risk assessment tools.
View Article and Find Full Text PDFArq Gastroenterol
September 2025
Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Objective: To verify the effect of physical exercise on the quality of life of patients with liver cirrhosis (LC).
Methods: the sample included controlled and randomized experimental studies of individuals with LC, at any stage of the disease, over 18 years of age, of both sexes, who performed any type of physical exercise compared to any other intervention or no intervention, with quality of life as the outcome assessed by the Chronic Liver Disease Questionnaire (CLDQ). The search for articles was conducted in 11 databases.